Search
GLP-1 Treatment Options in Rhode Island
A collection of 7 research studies where GLP-1 is the interventional treatment. These studies are located in the Rhode Island, United States. GLP-1 is used for conditions such as Obesity, Type 2 Diabetes and Diabetes.
1 - 7 of 7
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
Completed
Primary Objective:
To demonstrate the superiority of the insulin glargine/lixisenatide fixed ratio combination (FRC) versus GLP-1 receptor agonist (GLP-1 RA) in hemoglobin A1c (HbA1c) change.
Secondary Objectives:
To compare the overall efficacy and safety of the insulin glargine/lixisenatide FRC to GLP-1 RA on top of metformin (with or without pioglitazone, with or without sodium-glucose co-transporter 2 \[SGLT2\] inhibitor) in participants with type 2 diabetes.
To evaluate safety, efficacy... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/15/2022
Locations: Investigational Site Number 8400104, Warwick, Rhode Island
Conditions: Type 2 Diabetes Mellitus
Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus
Completed
Albiglutide is an analogue of glucagon-like peptide-1 (GLP-1), used to treat type 2 diabetes This study will test whether albiglutide affects the occurrence of major cardiovascular events such as heart attacks or strokes and other important medical outcomes in persons with type 2 diabetes, when used alone or added to other diabetes treatments.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
02/11/2019
Locations: GSK Investigational Site, Pawtucket, Rhode Island
Conditions: Diabetes Mellitus
Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes
Completed
The purpose of this study is to determine if albiglutide is safe and effective in the treatment of type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2016
Locations: GSK Investigational Site, Cumberland, Rhode Island +1 locations
Conditions: Diabetes Mellitus, Type 2
A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes
Completed
A study to determine the safety and efficacy of albiglutide in subjects with type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2016
Locations: GSK Investigational Site, East Providence, Rhode Island
Conditions: Diabetes Mellitus, Type 2
A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes
Completed
The purpose of this study is to determine the safety and efficacy of albiglutide in subjects with type 2 diabetes
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2016
Locations: GSK Investigational Site, Cumberland, Rhode Island +1 locations
Conditions: Diabetes Mellitus, Type 2
Safety and Efficacy Study of Albiglutide in Type 2 Diabetes
Completed
The purpose of this study is to determine whether albiglutide is effective in the treament of patients with type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2016
Locations: GSK Investigational Site, East Providence, Rhode Island
Conditions: Diabetes Mellitus, Type 2
Safety and Efficacy of Albiglutide in Type 2 Diabetes
Completed
The purpose of this study is to determine the safety, tolerability and efficacy of albiglutide in the treatment of type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2016
Locations: GSK Investigational Site, Cumberland, Rhode Island +1 locations
Conditions: Diabetes Mellitus, Type 2
1 - 7 of 7